Actinomycin D

Phase 2Small molecule

PPeking Union Medical College Hospital

Actinomycin D is one of 35 small molecule programs targeting Toripalimab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToripalimabRecruiting

RhabdomyosarcomaRecruiting

ToripalimabPhase 2

Recruiting

RhabdomyosarcomaPhase 2

Recruiting

Competition

Competitive Landscape

36 competitors in Rhabdomyosarcoma

#DrugCompanyPhaseTrials

Oncovin

Eli Lilly

Phase 3

16 2

Verzenio

Eli Lilly

Approved

—3

Cytoxan

BBaxter Healthcare Corporation

Phase 3

24 4

Camptosar

Pfizer

Phase 3

8 5

Adriamycin

Pfizer

Phase 3

6 6

Oncovin

Eli Lilly

Phase 3

5 7

Cosmegen

RRECORDATI GROUP

Phase 3

17 8

Ifex

BBaxter Healthcare Corporation

Phase 3

8 9

Neupogen

EEastern Cooperative Oncology Group

Phase 3

7 10

Vepesid

AAvyxa

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Rhabdomyosarcoma

NCT04388839

Q2 2030

Phase 1/2Recruiting

Rhabdomyosarcoma

NCT04625907

Clinical

Trials by Indication[1]

Rhabdomyosarcoma2 trials

Evolutionary Therapy for Rhabdomyosarcoma

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT04388839·12 enrolled

FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting·UUniversity of Birmingham·Phase 1/2·NCT04625907·1,672 enrolled

Toripalimab2 trials

Toripalimab Plus Actinomycin-D As Fist-Line Treatment for GTN with FIGO Score 7

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT06020755·17 enrolled

Toripalimab Plus Actinomycin-D as Fist-Line Treatment for GTN With FIGO Score 5-6

Recruiting·PPeking Union Medical College Hospital·N/A·NCT06028672·40 enrolled

Gestational Trophoblastic Tumor1 trial

Study of Paclitaxel Plus Cisplatin as the First-line Chemotherapy in High Risk Gestational Trophoblastic Tumor

Unknown status·WWeiguo Lv·Phase 3·NCT02639650·214 enrolled

Children1 trial

A Pharmacokinetic Study of Actinomycin-D and Vincristine in Children With Cancer

Unknown status·EEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)·Phase 4·NCT00491946·24 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Actinomycin D. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Actinomycin D compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Actinomycin D. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking Union Medical College Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking Union Medical College Hospital

Actinomycin D

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q2 2030

Trials by Indication[1]

Rhabdomyosarcoma2 trials

Toripalimab2 trials

Gestational Trophoblastic Tumor1 trial

Children1 trial

References

Drug Info

Quick Facts

Related News